Filtered By:
Drug: Methotrexate
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 289 results found since Jan 2013.
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial
Conclusions
Weekly docetaxel is not more effective than standard CMF as adjuvant treatment of older women with breast cancer and worsens QoL and toxicity.
ClinicalTrials.gov
NCT00331097.
Source: Annals of Oncology - March 26, 2015 Category: Cancer & Oncology Authors: Perrone, F., Nuzzo, F., Di Rella, F., Gravina, A., Iodice, G., Labonia, V., Landi, G., Pacilio, C., Rossi, E., De Laurentiis, M., D'Aiuto, M., Botti, G., Forestieri, V., Lauria, R., De Placido, S., Tinessa, V., Daniele, B., Gori, S., Colantuoni, G., Barni Tags: breast tumors Source Type: research
Methotrexate and biologics linked to higher zoster risk in psoriasis
The combination of methotrexate and biologics for the treatment of psoriasis may increase the risk of herpes zoster infection, according to a large, database cohort study published in JAMA Dermatology.
Analysis of medical records for 95,941 patients with psoriasis showed treatment with both...
Source: Skin and Allergy News - March 22, 2015 Category: Dermatology Tags: CME-candidate SAN Psoriasis SAN Journals SAN Clinical News SAN News FPN Journals FPN News Source Type: news
High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission
Conclusions
This study shows that the chance to reach drug-free remission in PsA patients is low. Discontinuation of DMARD therapy cannot be recommended in patients with PsA.
Source: Annals of the Rheumatic Diseases - March 5, 2015 Category: Rheumatology Authors: Araujo, E. G., Finzel, S., Englbrecht, M., Schreiber, D. A., Faustini, F., Hueber, A., Nas, K., Rech, J., Schett, G. Tags: Immunology (including allergy), Radiology, Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis, Clinical diagnostic tests, Radiology (diagnost Source Type: research
Key findings towards optimising adalimumab treatment: the concentration-effect curve
Conclusions
Adalimumab trough levels in a range of 5–8 μg/mL are sufficient to reach adequate clinical response. These levels are influenced substantially by concomitant MTX use.
Source: Annals of the Rheumatic Diseases - February 5, 2015 Category: Rheumatology Authors: Pouw, M. F., Krieckaert, C. L., Nurmohamed, M. T., van der Kleij, D., Aarden, L., Rispens, T., Wolbink, G. Tags: Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Epidemiology Clinical and epidemiological research Source Type: research
Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
Conclusions
SC golimumab safety up to 3 years remained consistent with that of other TNF antagonists. Golimumab 100 mg showed numerically higher incidences of serious infections, demyelinating events and lymphoma than 50 mg; safety follow-up up to year 5 continues.
Source: Annals of the Rheumatic Diseases - February 5, 2015 Category: Rheumatology Authors: Kay, J., Fleischmann, R., Keystone, E., Hsia, E. C., Hsu, B., Mack, M., Goldstein, N., Braun, J., Kavanaugh, A. Tags: Open access, Immunology (including allergy), Ankylosing spondylitis, Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Epidemiology, Calcium and bone Clinical and epidemiological research Source Type: research
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
Conclusions
Baricitinib improved the signs and symptoms of RA in methotrexate inadequate responders with active disease. Baricitinib was well tolerated with no unexpected safety findings through week 24.
Trial registration number
NCT01185353.
Source: Annals of the Rheumatic Diseases - January 7, 2015 Category: Rheumatology Authors: Keystone, E. C., Taylor, P. C., Drescher, E., Schlichting, D. E., Beattie, S. D., Berclaz, P.-Y., Lee, C. H., Fidelus-Gort, R. K., Luchi, M. E., Rooney, T. P., Macias, W. L., Genovese, M. C. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research
Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010
Conclusions
During the last decade, baseline RA disease activity level at the time of starting MTX as well as TNFi+MTX decreased from high to moderate. A more than twofold increase in 6-month remission rates was observed in both groups. Our findings indicate that clinicians have implemented modern, more aggressive treatment strategies, which hopefully will lead to better long-term disease outcomes.
Source: Annals of the Rheumatic Diseases - January 7, 2015 Category: Rheumatology Authors: Aga, A.-B., Lie, E., Uhlig, T., Olsen, I. C., Wierod, A., Kalstad, S., Rodevand, E., Mikkelsen, K., Kvien, T. K., Haavardsholm, E. A. Tags: Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research
Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
Conclusions
The possibility of remaining ADA-free for 1 year was demonstrated in established patients with RA with outcomes that ADA can be discontinued without flaring in 79% patients with deep remission, with similar rates in the ADA continuation group, and showed no functional or structural damage in patients with DAS28-ESR <3.2. ADA readministration to patients with flare during ADA discontinuation was effective.
Source: Annals of the Rheumatic Diseases - January 7, 2015 Category: Rheumatology Authors: Tanaka, Y., Hirata, S., Kubo, S., Fukuyo, S., Hanami, K., Sawamukai, N., Nakano, K., Nakayamada, S., Yamaoka, K., Sawamura, F., Saito, K. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research
Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients
Conclusions
In the first prospective study in JIA, long-chain MTX-PGs were associated with lower JADAS-27 at 3 months and during 1 year of MTX treatment. Erythrocyte MTX-PG could be a plausible candidate for therapeutic drug monitoring of MTX in JIA.
Source: Annals of the Rheumatic Diseases - January 7, 2015 Category: Rheumatology Authors: Ćalasan, M. B., den Boer, E., de Rotte, M. C. F. J., Vastert, S. J., Kamphuis, S., de Jonge, R., Wulffraat, N. M. Tags: Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research
Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis
Conclusions
In this first longitudinal study, we showed that an increase in erythrocyte-MTX-PG concentration was associated with a decreased DAS28 over 9 months in two cohorts, and is therefore a potential tool for therapeutic drug monitoring of MTX in RA.
Source: Annals of the Rheumatic Diseases - January 7, 2015 Category: Rheumatology Authors: de Rotte, M. C. F. J., den Boer, E., de Jong, P. H. P., Pluijm, S. M. F., Ćalasan, M. B., Weel, A. E., Huisman, A. M., Gerards, A. H., van Schaeybroeck, B., Wulffraat, N. M., Lindemans, J., Hazes, J. M. W., de Jonge, R. Tags: Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Epidemiology Clinical and epidemiological research Source Type: research
Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF{alpha} inhibitors and rituximab
Conclusions
Patients with long-standing high disease activity are at substantially increased risk of mortality. Effective control of disease activity decreases mortality. TNFα inhibitors and rituximab seem to be superior to conventional DMARDs in reducing this risk.
Source: Annals of the Rheumatic Diseases - January 7, 2015 Category: Rheumatology Authors: Listing, J., Kekow, J., Manger, B., Burmester, G.-R., Pattloch, D., Zink, A., Strangfeld, A. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Epidemiology Clinical and epidemiological research Source Type: research
Weekly docetaxel vs CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomised phase 3 ELDA trial.
CONCLUSIONS: Weekly docetaxel is not more effective than standard CMF as adjuvant treatment for older women with breast cancer, and worsens QoL and toxicity.
PMID: 25488686 [PubMed - as supplied by publisher]
Source: Ann Oncol - December 8, 2014 Category: Cancer & Oncology Authors: Perrone F, Nuzzo F, Di Rella F, Gravina A, Iodice G, Labonia V, Landi G, Pacilio C, Rossi E, De Laurentiis M, D'Aiuto M, Botti G, Forestieri V, Lauria R, De Placido S, Tinessa V, Daniele B, Gori S, Colantuoni G, Barni S, Riccardi F, De Maio E, Montanino A Tags: Ann Oncol Source Type: research
Secukinumab tames psoriatic arthritis in FUTURE 2 trial
BOSTON – Secukinumab improved quality of life and symptoms in patients with psoriatic arthritis, regardless of whether they had received prior anti-tumor-necrosis factor therapy or were concurrently receiving methotrexate, Dr. Ian B. McInnes reported at the annual meeting of the American College of...
Source: Skin and Allergy News - December 7, 2014 Category: Dermatology Tags: SAN Conference News RHEUM Conference News FPN Conferences IMN Conferences SAN Clinical News SAN News SAN Psoriasis RHEUM News RHEUM Spondyloarthropathies Source Type: news
Few psoriatic arthritis patients achieve minimal disease activity on methotrexate
BOSTON – It’s time to test whether methotrexate is really up to snuff as a first-line therapy for psoriatic arthritis, Canadian investigators say.
They base that recommendation on findings from a retrospective study showing that fewer than 18% of patients with psoriatic arthritis treated with...googletag.display('div-gpt-ad-cta');
Source: Skin and Allergy News - December 5, 2014 Category: Dermatology Tags: FPN Conferences IMN Conferences RHEUM Conference News SAN Conference News RHEUM News RHEUM Spondyloarthropathies SAN Clinical News SAN News SAN Psoriasis Source Type: news
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
Conclusions
Abatacept plus MTX demonstrated robust efficacy compared with MTX alone in early RA, with a good safety profile. The achievement of sustained remission following withdrawal of all RA therapy suggests an effect of abatacept's mechanism on autoimmune processes.
Trial registration number
NCT01142726.
Source: Annals of the Rheumatic Diseases - December 4, 2014 Category: Rheumatology Authors: Emery, P., Burmester, G. R., Bykerk, V. P., Combe, B. G., Furst, D. E., Barre, E., Karyekar, C. S., Wong, D. A., Huizinga, T. W. J. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research
